<DOC>
	<DOCNO>NCT01230749</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( body medication ) pharmacodynamics ( medication body ) treatment JNJ-41443532 relative treatment placebo type 2 diabetes mellitus participant .</brief_summary>
	<brief_title>A Study Multiple Oral Doses JNJ-41443532 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither investigator participant know treatment participant receives ) , multicenter ( study conduct multiple site ) , placebo ( inactive substance compare medication test whether medication real effect clinical study ) active comparator ( establish effective treatment compare medication test whether medication real effect clinical study ) control study ( placebo active comparator compare study medication test whether study medication real effect clinical study ) . The study consist 4 phase : screening phase ( 45 day administration study medication ) ; pre-dosing run-in phase ( phase clinical study commence treatment give . In study , participant 's glucose level observe run-in-phase : day 15 1 administration study medication ) ; treatment phase , follow-up phase ( 7 10 day last dose study medication ) . Approximately 88 participant enrol study . All participant randomly assign 4 treatment arm : JNJ-41443532 250 mg ; JNJ-41443532 1000 mg ; pioglitazone arm ; placebo . Safety evaluation include assessment adverse event include ocular assessment , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The maximum study duration participant approximately 12 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosed Type 2 Diabetes Mellitus ( T2DM ) least 3 month prior screen On stable treatment regimen least 2 month prior screen Medically stable basis physical examination , medical history , clinical laboratory test perform screen 2 day administration study medication Fasting plasma glucose ( FPG ) concentration 140 mg/dL 270 mg/dL 2 day administration study medication Agrees protocoldefined use effective contraception History type diabetes complication secondary form diabetes History eat disorder recent significant change body weight ( ie , equal 5 percent 3 month prior screen ) due diet nutritional treatment Taking antihyperglycemic agent ( insulin , exenatide , liraglutide ) within 6 month thiazolidinedione within 3 month 2 day administration study medication Clinically significant abnormal electrocardiogram History , currently active , significant illness medical disorder , retinal disease , tuberculosis Clinically important serious infection , positive serology screening ( hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus antibody )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>JNJ-41443532</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Placebo</keyword>
</DOC>